ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Though peak sales for Cretostimogene grenadenorepvec has not been identified. It is possible they are looking at peak sales of $3 billion
CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality authore dy IPO Kitchen on Seeking Alpha states the following:

While I am unable to find a peak sales estimate for cretostimogene, before Sesen Bio halted the development of Vicineum following a CRL from the FDA in 2021 due to concerns about elevated liver toxicity, the company estimated global peak sales of $3 billion for the drug for the same high-risk BCG-unresponsive NMIBC indication.